

Resource Summary Report

Generated by [dkNET](#) on Aug 26, 2026

DrugsAtFDA

RRID:SCR_010255

Type: Tool

Proper Citation

DrugsAtFDA (RRID:SCR_010255)

Resource Information

URL: <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm>

Proper Citation: DrugsAtFDA (RRID:SCR_010255)

Description: Database that contains information about FDA-approved brand name and generic prescription and over-the-counter human drugs and biological therapeutic products. Drugs@FDA includes most of the drug products approved since 1939. The majority of patient information, labels, approval letters, reviews, and other information are available for drug products approved since 1998. Dates of Coverage: 1939-present
Update frequency: Daily. Data imported from the Orange Book depends on its update frequency.

Synonyms: Drugs at FDA, Drugs@FDA

Resource Type: data or information resource, database

Resource Name: DrugsAtFDA

Resource ID: SCR_010255

Alternate IDs: nlx_156906

Record Creation Time: 20220129T080257+0000

Record Last Update: 20260821T193858+0000

Ratings and Alerts

No rating or validation information has been found for DrugsAtFDA.

No alerts have been found for DrugsAtFDA.

Data and Source Information

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Renner F, et al. (2026) Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer. *Molecular cancer therapeutics*, 25(4), 599.

Palazzo A, et al. (2023) Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis. *ESMO open*, 8(2), 101154.

Goetz MP, et al. (2023) Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*.

Li G, et al. (2020) A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients. *PloS one*, 15(9), e0238843.

Sundararajan T, et al. (2018) Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases. *Gene*, 641, 25.

McNamee LM, et al. (2017) Modeling timelines for translational science in cancer; the impact of technological maturation. *PloS one*, 12(3), e0174538.

Tanaka N, et al. (2017) Real world data of a veterinary teaching hospital in Japan: a pilot survey of prescribed medicines. *Veterinary record open*, 4(1), e000218.

Beijers L, et al. (2017) Spin in RCTs of anxiety medication with a positive primary outcome: a comparison of concerns expressed by the US FDA and in the published literature. *BMJ open*, 7(3), e012886.

Patel JM, et al. (2016) Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools. *Oncotarget*, 7(16), 22064.

Withycombe B, et al. (2016) Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source. *Journal of clinical epidemiology*, 77, 78.

Sit RW, et al. (2016) Hypertonic dextrose injections (prolotherapy) in the treatment of symptomatic knee osteoarthritis: A systematic review and meta-analysis. *Scientific reports*, 6, 25247.

Davis AP, et al. (2016) Generating Gene Ontology-Disease Inferences to Explore Mechanisms of Human Disease at the Comparative Toxicogenomics Database. *PloS one*, 11(5), e0155530.

Kuesel AC, et al. (2016) Research for new drugs for elimination of onchocerciasis in Africa. *International journal for parasitology. Drugs and drug resistance*, 6(3), 272.

Stegmann JL, et al. (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. *Leukemia*, 30(8), 1648.

Moskalev A, et al. (2015) Geroprotectors.org: a new, structured and curated database of current therapeutic interventions in aging and age-related disease. *Aging*, 7(9), 616.

Yu T, et al. (2015) Use of surrogate outcomes in US FDA drug approvals, 2003-2012: a survey. *BMJ open*, 5(11), e007960.

Murteira S, et al. (2014) Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications. *Journal of market access & health policy*, 2.

Glennon J, et al. (2014) Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. *European child & adolescent psychiatry*, 23(12), 1149.

O'Connor AB, et al. (2013) Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. *Pain*, 154(11), 2324.

Turner EH, et al. (2012) Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. *PLoS medicine*, 9(3), e1001189.